Clinical Trial Detail

NCT ID NCT03912831
Title Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications

cancer

Therapies

Cyclophosphamide + Fludarabine

KITE-439

Age Groups: adult senior

No variant requirements are available.